EORTC abstracts selected at EBCC-12 Virtual Congress
28 Sep 2020
3 EORTC abstracts were selected for the 12th European Breast Cancer Conference (EBCC-12) that will take place virtually on 2-3 October 2020.
Plenary Session
Keynote Lecture, Best and Late Breaking Abstract Presentations
Clinical Utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial
- Presentation number: ORAL-007
- Date: 2 October 2020, 13:50-14:00
- Speaker: Otto Metzger (USA)
Proffered Papers Session
Updated results of the MINDACT trial: 70-gene signature to guide de-escalation of chemotherapy in early breast cancer
- Presentation number: ORAL-021
- Date: 3 October 2020, 13:00-13:10
- Speaker: Emiel Rutgers (The Netherlands)
Screen-detected breast cancers have different tumor biology and better prognosis compared to interval breast cancers
- Presentation number: ORAL-011
- Date: 3 October 2020, 12:50-13:00
- Speaker: Josephine Lopes Cardozo (The Netherlands)
- MINDACT: 70-gene signature test as guidance for breast cancer treatment – video interview of Josephine Lopes Cardoso (source: ecancer)
EBCC-12 is a breast cancer conference where the very latest practice-changing research is presented. It aims to provide a unique multidisciplinary setting for all professionals with a common interest in breast cancer to discuss, debate, inform and educate themselves about this evolving disease.
To view the full two day programme, visit the EBCC-12 searchable programme.
Registration for the virtual event is still open. For further information click here.
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023